Intuitive Surgical (ISRG +2.2%) should be bought , albeit selectively, says William Blair. The firm recommends using the recent weakness to pick it up. Its channel checks indicate the outlook for robotic surgery has never been stronger, however Zytiga drug approval is likely years away. The firm maintains an Outperform rating.
More Stocks News
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/